Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
Yaerim Kim, Seungyeup Han
Korean J Intern Med. 2023;38(3):322-331. Published online 2023 Apr 25 DOI: https://doi.org/10.3904/kjim.2022.376
Citations to this article as recorded by 
Navigating advanced polycystic kidney disease: a case study of bilateral nephrectomy and life-saving transplant
Fathimath Suooda, Fathimath Maleesha, Fathmath Zuha Ali, Yulia Karpovich Ivanovna
International Journal of Research in Medical Sciences.2025; 13(3): 1264. CrossRef
Advancing therapeutic approaches and shaping future perspectives in the management of autosomal dominant polycystic kidney disease (ADPKD): Insights from clinical trials
Murali Krishna Moka, Deepalaxmi Rathakrishnan, D.K. Sriram, Melvin George
European Journal of Pharmacology.2025; 997: 177634. CrossRef
Tolvaptan-Loaded Tomato-Derived Nanovesicles: Characterization and Evaluation of Cytotoxicity, Wound Healing Potential and the Effects on Cyst Formation in Renal Cell Lines
Ramila Mammadova, Feby Pratiwi, Immacolata Fiume, Eslam Abdelrady, Olha Makieieva, Laura Zucaro, Francesco Trepiccione, Seppo Vainio, Gabriella Pocsfalvi
International Journal of Nanomedicine.2025; Volume 20: 6253. CrossRef
Evaluating physician confidence and barriers in prescribing tolvaptan for ADPKD management: a comprehensive online survey study
Niloufar Ebrahimi, Mehrbod Vakhshoori, Fouad Chebib, Pranav S. Garimella, Yasar Caliskan, Amir Abdipour, Sayna Norouzi
Journal of Nephrology.2024; 37(8): 2429. CrossRef